Dekker J J, Martens F, Schoemaker J
Research Institute for Endocrinology, Reproduction and Metabolism, Division of Reproductive Endocrinology and Fertility, Academic Hospital Vrije Universiteit, PO Box 7057, NL-1007 MB Amsterdam, The Netherlands.
Gynecol Endocrinol. 2001 Jun;15(3):210-8.
Decidual prolactin was directly determined in endometrial tissue in order to assess its potential role in improving the accuracy of the diagnosis of luteal-phase defect (LPD). Endometrial biopsies of 124 women with regular cycles (group 1) and 13 women with controlled ovarian hyperstimulation and progesterone-supported cycles (group 2) were evaluated in the secretory phase. In addition, decidual prolactin was measured in the luteal phase of the in vitro fertilization (IVF) cycles. The biopsies dated on or after day 25 showed a significant increase in the slope of the regression line of the cycle day versus decidual prolactin content (p < 0.05). Delayed endometrium was not characterized by a lower amount of decidual prolactin compared with biopsies with the same histological dating. On day 27 of the cycle, less prolactin was measured in the out-of-phase biopsies (p < 0.05). A large inter-individual variation in endometrial prolactin tissue content was noticed. In group 2 all biopsies but one were in phase. Compared to the in-phase biopsies of group 1, a significantly higher amount of prolactin was found in group 2. Production of endometrial prolactin in vivo is associated with decidualization of the stromal cells. However, because of the large inter-individual variation, determination of prolactin is not of adjuvant diagnostic value for clinical assessment of LPD. Three factors might explain the higher amount of decidual prolactin in group 2 compared to group 1: (1) a higher serum progesterone concentration owing to an increased production by multiple corpora lutea, or because of the administered progesterone; (2) increased estradiol levels and thus progesterone receptors; and (3) direct stimulation of decidualization by gonadotropins.
为了评估蜕膜催乳素在提高黄体期缺陷(LPD)诊断准确性方面的潜在作用,对子宫内膜组织中的蜕膜催乳素进行了直接测定。对124名月经周期规律的女性(第1组)和13名接受控制性卵巢过度刺激及孕激素支持周期的女性(第2组)的子宫内膜活检标本在分泌期进行了评估。此外,还测定了体外受精(IVF)周期黄体期的蜕膜催乳素。日期为第25天及以后的活检标本显示,周期日与蜕膜催乳素含量的回归线斜率显著增加(p<0.05)。与具有相同组织学日期的活检标本相比,子宫内膜延迟并非以蜕膜催乳素含量较低为特征。在周期的第27天,不同期活检标本中测得的催乳素较少(p<0.05)。注意到子宫内膜催乳素组织含量存在较大的个体间差异。在第2组中,除1例活检标本外,其余均处于同一期。与第1组同期活检标本相比,第2组中发现的催乳素含量显著更高。体内子宫内膜催乳素的产生与基质细胞的蜕膜化有关。然而,由于个体间差异较大,催乳素的测定对LPD的临床评估没有辅助诊断价值。有三个因素可以解释第2组中蜕膜催乳素含量高于第1组的原因:(1)多个黄体分泌增加或由于使用了孕激素导致血清孕酮浓度升高;(2)雌二醇水平升高,从而使孕酮受体增加;(3)促性腺激素对蜕膜化的直接刺激。